Related Experiment Video
Updated: Apr 19, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma
William J Magnuson1, Daniel G Petereit2, Bethany M Anderson3
1University of Wisconsin Department of Radiation Oncology, Madison, WI, U.S.A. wmagnuson@uwhealth.org.
Background/Aim:
The optimal adjuvant therapy for stage I uterine sarcoma remains unresolved and may consist of radiotherapy (RT), chemotherapy, hormonal therapy or observation. We analyzed the impact of adjuvant pelvic RT on overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), pelvic control (PC) and patterns of failure.
Patients And Methods:
A retrospective analysis of 157 patients with International Federation of Gynecology and Obstetrics FIGO stage I uterine sarcoma was performed. RT was given postoperatively to a dose of 45-51 Gy in 28-30 fractions.
Results:
The 5-year OS, CSS, DFS and PC was 58%, 62%, 47% and 72%, respectively. Adjuvant RT significantly improved PC (85% for RT group vs. 64% for non-RT group; p=0.02) but did not impact OS, CSS or DFS.
Conclusion:
The addition of adjuvant pelvic RT significantly improved PC for patients with stage I uterine sarcoma. As systemic therapies continue to improve, optimal locoregional control may result in improved patient outcomes.
